Trade Name: Daklinza
Generic Name: Daclatasvir Daklinza is a newly the Food and Drugs Administration (FDA) approved drug to treat patients with chronic hepatitis C genotype 3 infection.4 The company that markets the drug is Bristol-Myers Squibb, located in Princeton, New Jersey. The date of approval by the U.S FDA for the drug is July 24th, 2015. Although, Japan was the first country in the world to approve the drug , now the drug is being marketed in U.S, including northern and central America, Europe and Asia-Pacific region.2 Daklinza is a 60 mg tablet taken orally as prescribed by a health care provider with the normal dosage of once a day for the first 12 weeks. The drug should be stored at the room temperature between 68◦F to 77◦F or 20◦C to 25◦C. It is important to inform a health care provider about the medical conditions of the patient before taking the drug. It can be taken with or without food, but should be taken as indicated or it may cause side effects. Headache and fatigue are amongst the primary side effects, with other secondary side effects, including chest pain, confusion, nausea, diarrhea, etc. Daklinza is NS5A replication complex inhibitor.1 It is taken in combination with the antiviral medicine Sofosbuvir. The drug use for 12 weeks results in the Sustained Virologic Response (SVR) in HCV patients, meaning HCV particles no longer appear in the blood …show more content…
Adverse events were found at doses of 200 and 1000 mg/kg/day.3 In rabbits with pregnancy, Daklinza was administered orally at doses of 0, 40, 200, or 750 mg/kg/day.3 Maternal toxicity was observed at doses of 200 and 750 mg/kg/day. The AUC value was 22 fold higher than the recommended human dose at a dose of 40
Generic Name: Daclatasvir Daklinza is a newly the Food and Drugs Administration (FDA) approved drug to treat patients with chronic hepatitis C genotype 3 infection.4 The company that markets the drug is Bristol-Myers Squibb, located in Princeton, New Jersey. The date of approval by the U.S FDA for the drug is July 24th, 2015. Although, Japan was the first country in the world to approve the drug , now the drug is being marketed in U.S, including northern and central America, Europe and Asia-Pacific region.2 Daklinza is a 60 mg tablet taken orally as prescribed by a health care provider with the normal dosage of once a day for the first 12 weeks. The drug should be stored at the room temperature between 68◦F to 77◦F or 20◦C to 25◦C. It is important to inform a health care provider about the medical conditions of the patient before taking the drug. It can be taken with or without food, but should be taken as indicated or it may cause side effects. Headache and fatigue are amongst the primary side effects, with other secondary side effects, including chest pain, confusion, nausea, diarrhea, etc. Daklinza is NS5A replication complex inhibitor.1 It is taken in combination with the antiviral medicine Sofosbuvir. The drug use for 12 weeks results in the Sustained Virologic Response (SVR) in HCV patients, meaning HCV particles no longer appear in the blood …show more content…
Adverse events were found at doses of 200 and 1000 mg/kg/day.3 In rabbits with pregnancy, Daklinza was administered orally at doses of 0, 40, 200, or 750 mg/kg/day.3 Maternal toxicity was observed at doses of 200 and 750 mg/kg/day. The AUC value was 22 fold higher than the recommended human dose at a dose of 40